- Home
- Publications
- Publication Search
- Publication Details
Title
Temsirolimus: a safety and efficacy review
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume 11, Issue 5, Pages 861-879
Publisher
Informa Healthcare
Online
2012-08-06
DOI
10.1517/14740338.2012.713344
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Serum lactate dehydrogenase (LDH) as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma (RCC).
- (2017) A. J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Paronychia and Pyogenic Granuloma Induced by New Anticancer mTOR Inhibitors
- (2016) V Sibaud et al. ACTA DERMATO-VENEREOLOGICA
- Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors
- (2012) A. Naing et al. CLINICAL CANCER RESEARCH
- Serum Cholesterol and mTOR Inhibitors: Surrogate Biomarker or Epiphenomenon?
- (2012) D. C. Cho et al. CLINICAL CANCER RESEARCH
- Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma
- (2012) M. A. Davies et al. CLINICAL CANCER RESEARCH
- Increase in Cholesterol Predicts Survival Advantage in Renal Cell Carcinoma Patients Treated with Temsirolimus
- (2012) C. K. Lee et al. CLINICAL CANCER RESEARCH
- Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience
- (2012) V. Moreno Garcia et al. CLINICAL CANCER RESEARCH
- Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies
- (2012) T. Eisen et al. JNCI-Journal of the National Cancer Institute
- Therapy With m-TOR Inhibitors Decreases the Response to the Pandemic Influenza A H1N1 Vaccine in Solid Organ Transplant Recipients
- (2011) E. Cordero et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction
- (2011) Sachin Gupta et al. ANTI-CANCER DRUGS
- Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines
- (2011) Y Wang et al. BRITISH JOURNAL OF CANCER
- The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: A systematic review of the literature and meta-analysis
- (2011) Cristina Gomez-Fernandez et al. EUROPEAN JOURNAL OF CANCER
- Novel feedback inhibition of surface antigen synthesis by mammalian target of rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and therapy
- (2011) Chiao-Fang Teng et al. HEPATOLOGY
- Drug-Related Pneumonitis in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus
- (2011) Jose Pablo Maroto et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Temsirolimus in Pediatric Patients With Recurrent/Refractory Solid Tumors
- (2011) Sheri L. Spunt et al. JOURNAL OF CLINICAL ONCOLOGY
- Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial
- (2011) Sylvie Négrier et al. LANCET ONCOLOGY
- Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Clinical Evidence
- (2011) T. E. Hutson ONCOLOGIST
- Clinical Practice Guidelines for the Treatment of Metastatic Renal Cell Carcinoma: Today and Tomorrow
- (2011) A. M. Molina et al. ONCOLOGIST
- The mammalian target of rapamycin regulates cholesterol biosynthetic gene expression and exhibits a rapamycin-resistant transcriptional profile
- (2011) B. T. Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Temsirolimus in VEGF-refractory metastatic renal cell carcinoma
- (2010) M. J. MacKenzie et al. ANNALS OF ONCOLOGY
- Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-α
- (2010) S Yang et al. BRITISH JOURNAL OF CANCER
- Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks
- (2010) J. N. Sarkaria et al. CLINICAL CANCER RESEARCH
- The role of mTOR in memory CD8+ T-cell differentiation
- (2010) Koichi Araki et al. IMMUNOLOGICAL REVIEWS
- A Phase 1 Clinical Study of Temsirolimus (CCI-779) in Japanese Patients with Advanced Solid Tumors
- (2010) Y. Fujisaka et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- A Versatile Role of Mammalian Target of Rapamycin in Human Dendritic Cell Function and Differentiation
- (2010) M. Haidinger et al. JOURNAL OF IMMUNOLOGY
- Renal Cancer Resistance to Antiangiogenic Therapy Is Delayed by Restoration of Angiostatic Signaling
- (2010) R. S. Bhatt et al. MOLECULAR CANCER THERAPEUTICS
- Inhibitors of mTOR
- (2010) H.-J. Klumpen et al. ONCOLOGIST
- FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma
- (2010) V. E. Kwitkowski et al. ONCOLOGIST
- Clinical Outcome in Metastatic Renal Cell Carcinoma Patients After Failure of Initial Vascular Endothelial Growth Factor-Targeted Therapy
- (2010) Michael M. Vickers et al. UROLOGY
- Metastatic renal cell cancer treatments: An indirect comparison meta-analysis
- (2009) Edward J Mills et al. BMC CANCER
- Analysis of PTEN and HIF-1α and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-α
- (2009) Robert A. Figlin et al. CANCER
- Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma
- (2009) Premal H. Patel et al. Clinical Genitourinary Cancer
- Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: A case series
- (2009) Gianluigi Lunardi et al. CLINICAL THERAPEUTICS
- An Emerging Role of mTOR in Lipid Biosynthesis
- (2009) Mathieu Laplante et al. CURRENT BIOLOGY
- Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents
- (2009) Maurizio Zangari et al. JOURNAL OF CLINICAL ONCOLOGY
- Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma
- (2009) Holger Gerullis et al. MEDICAL ONCOLOGY
- Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies
- (2009) Janice P. Dutcher et al. MEDICAL ONCOLOGY
- Temsirolimus-Induced Glomerulopathy
- (2009) Hassane Izzedine et al. ONCOLOGY
- Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features
- (2008) J. Bellmunt et al. ANNALS OF ONCOLOGY
- Rapamycin down-regulates LDL-receptor expression independently of SREBP-2
- (2008) Laura J. Sharpe et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus
- (2008) J P Boni et al. BRITISH JOURNAL OF CANCER
- mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?
- (2008) C Le Tourneau et al. BRITISH JOURNAL OF CANCER
- Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients
- (2008) Shobha Rani Nalluri et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2
- (2008) Alfredo Toschi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started